Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrödinger, Inc. (Nasdaq: SDGR) is a computational science company focused on transforming molecular discovery for drug development and materials design. Its news flow reflects activity across software, collaborations, financial performance and a growing therapeutics portfolio, giving investors and industry observers insight into how its physics+AI platform is being applied in practice.
Recent press releases highlight progress in advancing Schrödinger’s physics+AI computational platform, including a predictive toxicology initiative, an AI-powered conversational interface in its Maestro graphical environment, and integration of Lilly’s TuneLab platform into LiveDesign, its cloud-native enterprise informatics environment. These updates illustrate how the company combines physics-based simulations with AI and machine learning to address challenges such as data scarcity in drug discovery.
Schrödinger’s news also covers collaborations and co-founded companies. Examples include expanded research agreements with Ajax Therapeutics, Lilly and Otsuka Pharmaceutical, as well as developments from Nimbus, Structure Therapeutics and Copernic Catalysts, all of which use Schrödinger’s platform in different ways. News items have described positive data for molecules such as zasocitinib, co-invented by Schrödinger and Nimbus, and the creation of a new ammonia synthesis catalyst in collaboration with Copernic.
On the corporate side, SDGR news includes quarterly financial results, updated financial guidance, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Pipeline updates for proprietary programs such as SGR-1505, SGR-3515, SGR-5573 and SGR-6016 appear alongside platform and partnership announcements, providing a combined view of software and drug discovery activities.
Investors and researchers can use the SDGR news page to follow earnings releases, platform enhancements, regulatory designations, collaborative milestones and governance disclosures that shape the company’s trajectory.
Schrödinger (NASDAQ: SDGR) has appointed Mannix Aklian as Executive Vice President, Chief Commercial Officer, and Global Head of Software Sales and Marketing. With over 25 years of experience in software sales and leadership within biopharmaceutical and technology industries, Aklian will oversee global account management teams and drive the company's software business growth. He joins from Certara, where he served as Senior Vice President of Global Software Sales, and previously held the position of CEO at LI, Inc. Aklian holds both B.S. and M.S. degrees in Molecular Biology from Tufts University.
Schrödinger (NASDAQ: SDGR) has granted restricted stock units (RSUs) for 7,051 shares to seven newly hired employees on May 21, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee. The RSUs follow a four-year vesting schedule: 25% vests after 12 months of continuous service, followed by equal yearly installments of 1/4 over the next three years. These grants serve as material inducement for employment compensation and comply with Nasdaq Listing Rule 5635(c)(4).
Schrödinger (SDGR) announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, June 4, 2025, at 1:25 p.m. ET. Investors and interested parties can access the live webcast through the "Investors" section of Schrödinger's website. The presentation recording will remain available on the company's website for approximately 90 days after the event.
Schrödinger (SDGR) announced upcoming presentations of initial Phase 1 clinical data for SGR-1505, their investigational MALT1 inhibitor, at two major conferences. The data will be presented at the European Hematology Association Annual Congress (June 12-15, 2025, Milan) and the International Conference on Malignant Lymphoma (June 17-21, 2025, Lugano).
The Phase 1 study evaluates SGR-1505's safety, tolerability, and anti-tumor activity in patients with relapsed/refractory B-cell malignancies. The presentations will include initial safety, pharmacokinetic and pharmacodynamic data, plus preliminary efficacy data across various dosing levels. The company will host a webcast to discuss the data on June 12, 2025, at 8:00 a.m. ET.
Schrödinger (NASDAQ: SDGR) announced its upcoming participation in the BofA Securities 2025 Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, May 14, 2025, at 4:40 p.m. ET. Interested parties can access the live webcast through the "Investors" section of Schrödinger's website, where it will remain available for approximately 90 days after the event.
Schrödinger (SDGR) presented preclinical data for two cancer drug candidates at the AACR Annual Meeting 2025. The first candidate, SGR-3515, a Wee1/Myt1 co-inhibitor, showed improved anti-tumor activity compared to existing monotherapy inhibitors, with optimized dosing schedules allowing efficacy preservation while minimizing side effects. Initial Phase 1 trial data for SGR-3515 in advanced solid tumors is expected in H2 2025.
The second candidate, SGR-4174, a novel SOS1 inhibitor targeting KRAS mutations, demonstrated high selectivity and strong tumor growth inhibition both as monotherapy and in combination with MEK or KRAS inhibitors. The company also presented data on a new computational method for predicting responses to Wee1-based drug combinations, particularly in head and neck cancers.
Schrödinger (SDGR) has scheduled the release of its first quarter 2025 financial results for Wednesday, May 7, 2025, following the close of financial markets. The company will hold a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast through the company's website's 'Investors' section, where it will remain available for approximately 90 days after the event.
Schrödinger (Nasdaq: SDGR) has announced new inducement grants to seven newly hired employees on April 16, 2025. The grants include:
- A non-statutory stock option to purchase 3,300 shares (exercise price: $25.21 per share) granted to one employee
- Restricted stock units (RSUs) for 12,866 shares granted to six employees
The grants were made under the company's 2021 Inducement Equity Incentive Plan. The stock option has a ten-year term with 25% vesting after 12 months and the remainder vesting monthly over 36 months. RSUs vest over four years, with 25% vesting after 12 months and the remaining vesting yearly over three years.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
